For years, scientists have been sounding the alarm about a global antibiotic resistance crisis. Annually, this resistance leads to over 4.95 million deaths worldwide — a silent killer that regrettably claims countless lives, many of which could be saved.
Source: Click here
What is the Antibiotic Resistance Crisis
Antibiotics, hailed as one of the greatest medical advancements of the 20th century, have saved millions of lives since Alexander Fleming’s accidental discovery. A mere century ago, when life expectancy averaged around 55 years, antibiotics arguably played the greatest role in extending human lifespans. However, the escalating threat of antibiotic resistance, a natural ability of bacteria to outsmart the very drugs designed to combat them, now threatens to undo these medical triumphs.
Antibiotics are medications used to treat bacterial infections. They function by inhibiting the growth of pathogenic bacteria, allowing the body's immune system to fight off the infection. The concept of 'resistance' elucidates to how bacteria in our body possess a natural ability to rapidly evolve and outsmart specific antibiotic drugs designed to eliminate them. This phenomenon causes certain antibiotic treatments to become ineffective over time, necessitating their constant replacement with new drugs.
The perpetual evolution of bacterial strains, coupled with overprescription of antibiotics in our healthcare system and the excessive use of antibiotics in livestock, has accelerated the 'resistance cycles,' posing a hefty challenge for pharmaceutical companies. Scientists are struggling to keep up with the urgent need to replace antibiotics that have lost their efficacy, creating a never-ending game of catch-up.
The Growing Threat
Antibiotic resistance is no longer a distant threat as it stands at the front door of the very foundations of modern medicine.
Medical procedures such as organ transplants, chemotherapy, and surgeries like caesarean sections have become considerably riskier in the absence of effective antibiotics for infection prevention and treatment, adding to the gravity of the situation.
The consequences of the antibiotic crisis are now far-reaching, where resistant infections related deaths are projected to rise to 10 million by 2050 if left unchecked. Equally concerning is the anticipated global economic burden, set to reach US$100 trillion by 2050. The misuse of antibiotics, aggravated by patients utilizing them for viral infections or neglecting prescribed courses, further compounds the challenge.
As approximately one-third of outpatient antibiotic prescriptions are ineffective today, this resistance leads to extended hospital stays, higher medical expenses, and increased mortality rates. It places a substantial burden on both economic productivity and healthcare systems — a matter of profound concern.
Challenges in Developing New Antibiotics
Despite the dire need for novel antibiotics, their development has stalled. The problem is straightforward: Companies that have invested billions to develop these drugs have not found a way to make money selling them. Unlike medicines for chronic conditions like diabetes or rheumatoid arthritis, antibiotics are typically prescribed for just days or weeks. Additionally, these drugs become obsolete within a relatively short time frame, around 3-5 years, before their cash flow comes to a stop. For these reasons, the development of new antibiotics has slowed dramatically in recent years, causing the pipeline for such drugs to dwindle, naturally limiting our options to combat resistance.
Addressing the Crisis
Addressing the antibiotic crisis requires a multi-faceted approach. First, we must reduce the overuse and misuse of antibiotics through education, improved diagnostic tools, and stricter prescribing guidelines. As a substantial portion of antibiotics, approximately 80%, is employed in agriculture, primarily to promote yields, these sectors should be a core focus.
Second, research and development of new antibiotics is imperative, necessitating incentives for pharmaceutical companies and public funding. Finally, we must emphasize infection prevention and control measures, such as proper hygiene, vaccination, and improved sanitation. Tracking methodologies are crucial to comprehending the incidence, prevalence, mortality, and cost of resistant bacterial infections.
Business Opportunities in the Fight Against Antibiotic Resistance
The World Health Organization has designated antibiotic resistance as one of humanity's top ten global health threats. However, this crisis presents not only a medical challenge but also a long term investment opportunity with a social cause. Despire pharmaceutical giants like Novartis and Allergan abandoning the sector and many smaller firms are on track toward insolvency, recent breakthroughs in biotechnology and genomics are paving the way for innovative antibiotic therapies. Examples include:
Cellectis: pioneering a groundbreaking antibiotic approach using genetically engineered CAR-T cells to combat drug-resistant bacteria.
Curetis: working on improving tests to help doctors choose the right antibiotics for pneumonia acquired in hospitals.
Unyvero: uses a fast PCR method to find out which bacteria are resistant to antibiotics.
The global antibiotic market is projected to reach US$50 billion by 2029, driven by the increasing demand for effective treatments and an expected financial incentives from governments and healthcare organizations. As the crisis escalates, the market for new antibiotics and related biotechnologies is likely to expand, offering new business opportunities.
With the staggering projection of 10 million annual deaths from antibiotic-resistant infections by 2050, it is imperative that we recognize the market's potential to channel funds toward addressing this global crisis.